> ## Content Index > Fetch the complete content index at: https://www.moatmarginresearch.com/llms.txt > Use this file to discover other available public pages before exploring further. # Aurobindo Pharma Moat Analysis: Score & Risks - URL: https://www.moatmarginresearch.com/aurobindo-pharma-moat/ - Published: 2026-08-02T13:12:54.000Z - Updated: 2026-08-22T05:14:26.000Z - Author: A K Karthikeyan - Tags: First-pass note, Coverage Moat Note · First-pass ## Aurobindo Pharma Ltd. A first-pass moat teardown of Aurobindo Pharma Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it. **Moat & Margin**2 Aug 2026 First-pass · \~4 min 5.08 / 10 NARROWVertical-integration First-pass narrow read — primary edge in Intangible Assets. Provisional, single-pass evidence. Provisional score · subject to modification based on new evidence Aurobindo Pharma Ltd. scores **5.08** on MoatSCORE 6.0 — a narrow moat in Pharma. This is a **first-pass note**: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued. The teardown ## Seven dimensions of moat Ordered by contribution. Each dimension carries a verified filing quote, graded **\[M\]** mechanism or **\[O\]** outcome. D5Intangible Assets6 M · Mechanism✓ Verified verbatim “CuraTeQ has steadfastly built momentum with biosimilar approvals in 2025 and is advancing a robust next-wave pipeline of biosimilars across oncology and immunology segments” **Aurobindo Pharma Ltd.** · Investor Presentation · p.13 D3Cost Advantage5.7 M · Mechanism✓ Verified verbatim “Leveraging our expertise in process chemistry and the advantages of large-scale production, we have positioned ourselves as a cost-effective provider of API” **Aurobindo Pharma Ltd.** · FY23 Annual Report · p.7 D6Efficient Scale5.5 M · Mechanism✓ Verified verbatim “the scales at which we are attempting to become a CMO is a key differentiator in India, right. Now, if you look at my prod” **Aurobindo Pharma Ltd.** · Earnings Call · p.13 D4Price Discretion5.2 M · Mechanism✓ Verified verbatim “Our large product portfolio helps us to maintain optimally the price stability.” **Aurobindo Pharma Ltd.** · Earnings Call · p.4 D1Network Effects4.5 O · Outcome✓ Verified verbatim “API business posted revenues decline of 4% YoY impacted primarily by market conditions” **Aurobindo Pharma Ltd.** · Investor Presentation · p.11 4 quotes extracted here — not one mechanism-class. The evidence is outcome-only. D2Switching Costs4.5 M · Mechanism✓ Verified verbatim “we will be into the commercial global supply chain right from Day 1 after receiving the regulatory approvals. And that is the business model of TheraNym.” **Aurobindo Pharma Ltd.** · Earnings Call · p.17 D7Counter-PositioningExcluded— Excluded for this archetype. D8Ungoverned RiskUnscored · Layer 2.5 D8 rating: **ADEQUATE**. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed. The barrier gate ## The barrier gate — first-pass Replication — can a rival copy it?6.5 How hard it is for a rival to copy the edge (first-pass estimate). Bypass — can a rival route around it?6.0 How easily a rival can route around the edge (first-pass estimate). Effective barrier 6.0 — clears the gate. First-pass estimate. What would change our mind 1. **Deep two-pass review.** This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read. 2. **The barrier gate.** A firmer replication or bypass estimate is the most likely thing to shift the band. 3. **Adverse events.** Any governance, regulatory or funding shock captured in D8 could re-rate the fade window. First-pass note — provisional single-pass MoatSCORE 6.0 read, not the full deep dive. Educational research, not investment advice; no buy/sell recommendation, no price target. Moat & Margin is not a SEBI-registered Research Analyst or Investment Adviser. **Where this note fits.** This company is one of **113 Indian companies** we have scored for moat durability — 88 narrow, 25 narrow-trending-wide, none wide. The full ranked read: [Wide-Moat Stocks in India: We Scored 113 Companies and Found None](https://www.moatmarginresearch.com/wide-moat-stocks-india/). Every score, dimension by dimension, is free in the [Moat Screener](https://www.moatmarginresearch.com/moat-screener/).